Overview
Tamoxifen for Solid Pseudopapillary Tumor of the Pancreas
Description
Solid pseudopapillary tumor of the pancreas (SPTP) is a rare neoplasm, predominantly affecting young females, with unclear pathogenesis and hormonal receptor (estrogen/progesterone receptor) expression potentially influencing tumor behavior. While surgical resection is the standard treatment, patients with advanced, metastatic, or recurrent disease lack effective therapies. Case reports suggest tamoxifen, a selective estrogen receptor modulator, may improve outcomes in hormone receptor-positive SPTP. This trial aims to evaluate tamoxifen's efficacy and safety in advanced SPTP.
Eligibility
Inclusion Criteria:
- Age 14-80 years.
- Histologically confirmed advanced SPTP with ER/PR+.
- Advanced disease:
- Unresectable primary tumor or distant metastasis (liver, lung, peritoneum, etc.).
- Recurrent or refractory after prior surgery/systemic therapy.
- ≥1 measurable lesion.
- ECOG performance status 0-2.
- Life expectancy ≥1 month.
- Able to comply with study visits and oral medication.
Exclusion Criteria:
- Non-SPTP pathology.
- Active gastrointestinal inflammation/infection (e.g., pancreatitis).
- Pregnancy/lactation.
- Severe organ dysfunction (renal, cardiac, hepatic, or pulmonary).
- Uncontrolled comorbidities (e.g., CNS disorders, unstable angina).
- Conditions compromising patient safety or data integrity.